Nanexa AB announced that the Clinical Trial Application for the Phase I study of NEX-22 in patients with type 2 diabetes has been received and validated by the European Medicines Agency (EMA).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.928 SEK | -0.85% |
|
+1.98% | -24.55% |
Jun. 11 | Nanexa AB Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes | CI |
May. 15 | Nanexa AB Elects Hanna Tilus as Members of the Board | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.55% | 12.12M | |
+8.38% | 248M |
- Stock Market
- Equities
- NANEXA Stock
- News Nanexa AB
- Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA